PL2457563T3 - Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego - Google Patents

Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego

Info

Publication number
PL2457563T3
PL2457563T3 PL12156190T PL12156190T PL2457563T3 PL 2457563 T3 PL2457563 T3 PL 2457563T3 PL 12156190 T PL12156190 T PL 12156190T PL 12156190 T PL12156190 T PL 12156190T PL 2457563 T3 PL2457563 T3 PL 2457563T3
Authority
PL
Poland
Prior art keywords
zero
dosage forms
solid dosage
modified release
release solid
Prior art date
Application number
PL12156190T
Other languages
English (en)
Inventor
Suneel Kumar Rastogi
Justin Clark Meadows
Vishal Kumar Gupta
Original Assignee
Mallinckrodt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Llc filed Critical Mallinckrodt Llc
Publication of PL2457563T3 publication Critical patent/PL2457563T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12156190T 2006-05-09 2007-05-09 Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego PL2457563T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79888906P 2006-05-09 2006-05-09
US85622606P 2006-11-01 2006-11-01

Publications (1)

Publication Number Publication Date
PL2457563T3 true PL2457563T3 (pl) 2017-09-29

Family

ID=38659385

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12156190T PL2457563T3 (pl) 2006-05-09 2007-05-09 Stałe postacie dawkowania o zmodyfikowanym uwalnianiu rzędu zerowego
PL12156178T PL2457562T3 (pl) 2006-05-09 2007-05-09 Stałe postacie dawkowania leku o zmodyfikowanym uwalnianiu o kinetyce rzędu zerowego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL12156178T PL2457562T3 (pl) 2006-05-09 2007-05-09 Stałe postacie dawkowania leku o zmodyfikowanym uwalnianiu o kinetyce rzędu zerowego

Country Status (9)

Country Link
US (2) US20090110728A1 (pl)
EP (3) EP2020995A2 (pl)
JP (1) JP2009536654A (pl)
AU (1) AU2007249947B2 (pl)
CA (1) CA2651798C (pl)
ES (2) ES2626632T3 (pl)
MX (2) MX2008014059A (pl)
PL (2) PL2457563T3 (pl)
WO (1) WO2007133583A2 (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
NZ544826A (en) 2003-07-25 2008-07-31 Warner Chilcott Co Inc A doxycycline metal complex in a solid dosage form
AU2006206359B2 (en) * 2005-01-21 2011-03-31 Allergan Pharmaceuticals International Limited A tetracycline metal complex in a solid dosage form
WO2008103538A1 (en) * 2007-02-21 2008-08-28 Connected Health Systems, Llc Treating adhd and other diseases involving inflammation
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
WO2008154339A2 (en) 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
AU2009265099A1 (en) 2008-07-01 2010-01-07 Lupin Limited Sustained release pharmaceutical compositions comprising Quetiapine
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010077925A2 (en) * 2008-12-16 2010-07-08 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order biphasic, ascending or descending drug delivery of methylphenidate
EP2564839B1 (en) 2009-01-09 2016-05-11 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
AU2011256928A1 (en) 2010-05-24 2012-12-20 Lupin Limited Extended release formulation of pramipexole
DE102010033527A1 (de) 2010-08-05 2012-02-09 Acino Pharma Ag Quetiapin-Tabletten
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
MX2013004227A (es) * 2010-10-21 2013-05-30 Galderma Sa Tableta de liberacion sostenida y proceso para prepararla.
ES2498217T5 (es) 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
PL2826467T3 (pl) 2010-12-22 2018-01-31 Purdue Pharma Lp Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2663294B1 (en) 2011-01-11 2015-09-30 Capsugel Belgium NV New hard capsules comprising pullulan
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2012129551A1 (en) 2011-03-23 2012-09-27 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CN103648487B (zh) 2011-05-13 2019-04-19 Eb Ip希博里塔布斯有限责任公司 药物递送系统
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
CN107049979B (zh) 2011-09-30 2020-08-14 持田制药株式会社 易服用性固体制剂
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
FR2986431B1 (fr) * 2012-02-03 2017-03-17 Servier Lab Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques
EP4233915A3 (en) * 2012-02-08 2023-09-20 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
US20150231080A1 (en) 2012-09-10 2015-08-20 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CN104069502B (zh) * 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA2973099C (en) * 2015-01-12 2021-09-14 Enteris Biopharma, Inc. Solid oral dosage forms
CN105982861B (zh) * 2015-02-11 2020-04-14 北京科信必成医药科技发展有限公司 一种阿奇霉素无水吞服掩味颗粒剂
US20180360817A1 (en) 2015-12-31 2018-12-20 Cadila Healthcare Limited Extended release osmotic dosage form comprising high methylphenidate hydrochloride load
ES2641308B1 (es) * 2016-05-05 2018-09-11 Products & Technology, S.L. Comprimidos de metilfenidato de liberación retardada
JP2018095566A (ja) * 2016-12-08 2018-06-21 アサヒグループ食品株式会社 水溶性機能性原料含有組成物、ソフトカプセル、及びソフトカプセルにおける水溶性機能性原料の減成抑制方法
HRP20250979T1 (hr) 2017-04-14 2025-10-24 Capsugel Belgium Nv Pululan kapsule
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
CN113557008A (zh) 2018-10-29 2021-10-26 弗劳恩霍夫应用研究促进协会 具有持续活性的四环素类络合物
CN110025570A (zh) * 2019-05-25 2019-07-19 陕西中医药大学 新型中药蜂蜡块
CN110585154B (zh) * 2019-10-17 2021-07-02 武汉光谷亚太医药研究院有限公司 一种琥珀酸美托洛尔微丸压片的方法
WO2022241255A1 (en) * 2021-05-14 2022-11-17 Ocumedic, Inc. Extended-wear silicone hydrogel contact lenses and uses thereof
US20230240998A1 (en) * 2021-12-22 2023-08-03 Hikma Pharmaceuticals Usa Inc. Tofacitinib extended release formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US7094469B2 (en) * 2001-08-28 2006-08-22 Mykrolis Corporation Porous or non-porous substrate coated with an immobilized polymeric composition having sulfonyl groups and hydrophilic functional groups and process
MXPA04006163A (es) * 2001-12-20 2004-11-01 Pharmacia Corp Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
BRPI0513598A (pt) * 2004-07-26 2008-05-13 Teva Pharma formas de dosagem em comprimidos revestidos de liberação entérica
UA88477C2 (ru) * 2004-08-13 2009-10-26 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение

Also Published As

Publication number Publication date
PL2457562T3 (pl) 2017-09-29
EP2457563A1 (en) 2012-05-30
CA2651798C (en) 2015-07-21
WO2007133583A2 (en) 2007-11-22
AU2007249947A1 (en) 2007-11-22
ES2627127T3 (es) 2017-07-26
EP2457562B1 (en) 2017-04-05
EP2457563B1 (en) 2017-03-22
JP2009536654A (ja) 2009-10-15
AU2007249947B2 (en) 2013-03-21
MX2008014059A (es) 2008-11-14
MX350380B (es) 2017-09-05
ES2626632T3 (es) 2017-07-25
EP2020995A2 (en) 2009-02-11
US20090110728A1 (en) 2009-04-30
WO2007133583A3 (en) 2008-05-22
CA2651798A1 (en) 2007-11-22
EP2457562A1 (en) 2012-05-30
US20190358164A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PL2457562T3 (pl) Stałe postacie dawkowania leku o zmodyfikowanym uwalnianiu o kinetyce rzędu zerowego
IL199191A0 (en) Modified release ibuprofen solid oral dosage form
PL2384754T3 (pl) Farmaceutyczne postacie dawkowania
ZA200809546B (en) Pharmaceutical compounds
ZA200810164B (en) Sustained release pharmaceutical dosage form containing phenylphrine
IL196396A0 (en) Controlled-release formulations
GB0610680D0 (en) Therapeutic compounds
GB0608820D0 (en) Pharmaceutical compounds
IL194366A0 (en) Solid dosage formulations
PL2002828T3 (pl) Stały preparat farmaceutyczny
GB0616794D0 (en) Solid dosage form
GB0608176D0 (en) Pharmaceutical Compounds
GB0608184D0 (en) Pharmaceutical compounds
GB0608264D0 (en) Pharmaceutical compounds
GB0608175D0 (en) Pharmaceutical Compounds
GB2444064B (en) Braking mechanism
PL1984570T3 (pl) Urządzenie pługa
GB0622892D0 (en) Pharmaceutical compounds
GB0625682D0 (en) Pharmaceutical compounds
IL178378A0 (en) Extended release pharmaceutical compositions
GB0608178D0 (en) Pharmaceutical compounds
GB0615299D0 (en) Pharmaceutical compounds
GB0608397D0 (en) Pharmaceutical compounds
GB0625431D0 (en) Pharmaceutical compounds
GB0625668D0 (en) Pharmaceutical compounds